Catalyst Pharmaceuticals Announces Topline Results From Two-Part Phase 1 Clinical Study Of Vamorolone In Healthy Adult Volunteers
The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.